SELECTED CLINCIAL TRIALS - Principal Investigator GU Research
PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Non-metastatic Castration-Resistant Prostate Cancer
Randomized phase IB/II study of enzalutamide with and without Ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression
DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib With Background Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With DNA Damage Repair Deficiencies
A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4
A Phase 2 Open-label Extension Study for Subjects with Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies (STRONG) Module A – Post-Chemotherapy Urothelial and Non-Urothelial Carcinoma of the Urinary Tract
A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride
An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid)
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591(177Lu-J591) and Ketoconazole in Patients with High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Phase I Trial of Apalutamide plus Abiraterone acetate, Docetaxel, and Prednisone in Patients with Metastatic Castrate Resistant Prostate Cancer(mCRPC)
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Asymptomatic, previously untreated, metastatic Castrate-Resistant Prostate Cancer
A Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation Therapy followed by Docetaxel in Men with PSA Recurrent Prostate Cancer after Radical Prostatectomy (STARTAR)
An Extended/Phase 2, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Tolerability of Proxalutamide (GT0918) in Subjects with Metastatic Castrate Resistant Prostate Cancer (mCRPC) who Failed Either Abiraterone or Enzalutamide
A Randomized, Double-blind,Placebo-controlled, Multicenter Phase III Study of Olaparib Plus AbirateroneRelative to Placebo Plus Abiraterone as First-line Therapy in Men withMetastatic Castration-resistant Prostate Cancer
A Randomized Phase 3, Open-label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer
An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1 and CTLA-4)used as Monotherapy or in Combination in Patients with Cancer
Randomized phase IB/II study of enzalutamide with and without ribociclib in patients with metastatic castrate resistant, chemotherapy naïve prostate cancer that retains RB expression Prostate Cancer Clinical Trials Consortium, LLC (PCCTC)
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses ofAZD4635 Both as Monotherapy and in Combination with Durvalumab in Patients with Advanced Solid Malignancies
A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
VISION: An International, Prospective, Open-Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients with Progressive PSMA-Positive Metastatic Castration Resistant Prostate Cancer (mCRPC)
A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
A Phase 1, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of KPG-121 in Combination with Enzalutamide in Adult Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 3, multi-center, randomized, placebo-controlled, double-blind study of Atezolizumab (Anti LD-L1 Antibody) in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen
A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer
Androgen Deprivation Therapy with or without Radium-223 dichloride in Patients with Newly Diagnosed Metastatic Prostate Cancer with Bone Metastases
A Phase 1/2A, Multicenter, Open-Label Study of LYC-55716 In Adult Subjects With Locally Advanced Or Metastatic Cancer
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
MVT-601-3202 HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer
A randomized, double-blind, placebo-controlled Phase III study of ODM-201 versus placebo in addition to standard androgen deprivation therapy and docetaxel inpatients with metastatic hormone-sensitive prostate cancer
A Phase 1, open-label trial to evaluate the safety and immunogenicity of PAN-301-1 in Cancer Patients
A long term follow up to eRADicAte, an Open label phase two study of RADium Ra223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone in Castration-Resistant(Hormone-Refractory) Prostate Cancer Subjects with Symptomatic Bone Metastasis
A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
A phase I/2 multicenter - open -label, two stage study to evaluate the safety, tolerability and pharmacokinetics of study drug in subjects with metastatic castrate resistant prostate cancer
A multicenter, randomized, open-label phase 3 study of rucaparib versus physician's choice of therapy for patients with mCRPC associated with homologous recombination deficiency
TRITON 2:A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients with Metastatic Castration-Resistant Prostate Cancer on SoluMatrix™ Abiraterone Acetate 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid) as Compared to Zytiga® 1,000 mg (4 x 250 mg qd) with Prednisone (5 mg bid)
APhase 3 Randomized, Double-blind, Multi-center Study of Adjuvant NivolumabVersus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma(CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma
A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-DeprivationTherapy
ASudy of Galeterone Compared to Enzalutamide In Men Expressing AndrogenRecptr Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)
AMulticenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study ofARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study ofFirst-Line MEDI4736 Monotherapy and MEDI4736 in Combination with TremelimumabVersus Standard of Care Chemotherapy in Patients with Unresectable Stage IVUrothelial Cancer
Aphse II single arm clinical trial of nivolumab (BMS-936558) in subjects withmetastatic or unresectable urothelial cancer who have progressed or recurredfollowing treatment with a platinum agent
Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer
A phase 2, randomized, 3-arm study of abiraterone acetate alone, abiraterone acetate plus degarelix, a GnRH antagonist, anddegarelix alone for patients with prostate cancer with a rising PSA or a risingPSA and nodal disease following definitive radical prostatectomy
Osteonecrosisof the Jaw (ONJ) Case Registry
Efficacyand Safety Study of BAY1841788 (ODM-201) in Men With High-risk Non-metastaticCastration-resistant Prostate Cancer (ARAMIS)
ARandomized, Open-Label, Phase 2 Trial Of Sipuleucel-T With concurrent VersusSuential Administration Of Abiraterone Acetate Plus Prednisone In Men WithMetastatic Castrate Resistant Prostate Cancer
APhase 2, Open-label, Multicenter Study of PSMA ADC in Subjects with MetastaticCastration-resistant Prostate Cancer (mCRPC)
A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone with Placebo Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
APhase 2, Open-Label, Single-Arm, Multidose Study to Investigate the Effects ofOrteronel on the QT/QTc Interval in Patients With MetastaticCastration-Resistant Prostate Cancer
AStudy in Japan and Ex-Japan to Characterize the Pharmacokinetic andPharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive PaientsWith Castration-Resistant Prostate Cancer
A Registry for Patients Treated on the Clinical Trial TAX 35032015 Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)
ASingle-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 inPatients With Castration-Resistant Prostate Cancer Progressing on Enzalutamideor Abiraterone
ARandomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With AbirateroneAcetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer(CRPC)
REASSURE- Radium-223 alpha Emitter Agent in Safety Study in mCRPC population for long-term evaluation
AnIternational Phase 3 Randomized Trials of Autologous Dendritic CellInotherapy (AGS-003) Plus Standard Treatment of Advanced Renal CellCarcinoma. (ADAPT)
AdjuvanAxitinib Treatment of Renal Cancer: A Randomized Double-blind Phase 3 Study ofAdjuvant Axitinib vs. Placebo in Subjects at High Risk of Recurrent RCC
Are-treatment safety study of radium-223 dichloride in subjectswithcastration-resistant prostate cancer with bone metastases who received
QualitativeIterviews to Support PRO Measurement in Patients Diagnosed with Cancer-RelatedCachexia
APhase 3, Randomized, Double-Blind, Placebo-Controlled Study of AbirateroneAcetate (CB7630) Plus Prednisone in Asymptomatic or Mildly Symptomatic Patientswith Metastatic Castration-Resistant Prostate Cancer
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients with LocallyAdvanced or Metastatic Urothelial Bladder Cancer
A Multicenter, Open-label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advance Prostate Cancer Without Radiologic Evidence of Metastatic Disease
A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide,Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-RiskNonmetastatic Prostate Cancer Progressing After Definitive Therapy
Randomized, Phase 2, Open-Label Study Evaluating DN24-02 As Adjuvant Therapy In SubjectsWith High Risk Her2 + Urothelial Carcinoma
A Randomized, Double-Blind, Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination with OGX-427 or Placebo in Patients with Advanced Transitional Cell Carcinoma
A Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen (OGX-011) to Cabazitaxel/Prednisone for Second-Line Chemotherapy in Men with Metastatic Castrate Resistant Prostate Cancer
A Phase III, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Pazopanib in Combination with Weekly Paclitaxel vs Weekly Paclitaxel in Subjects with Advanced Urothelial Cancer who have Received Prior Platinum Chemotherapy for Metastatic Disease
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study of Continued Enzalutamide Treatment Beyond Progression in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer2014 Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
A Randomized, Double-Blind, Phase 3, Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men with Asymptomatic or Minimally Symptomatic Metatstatic, Castrate-Resistant Prostate Cancer
A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs Bicalutamide in Men with Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy
A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH)Antagonist, for Patients With Localized Prostate Cancer Requiring Neo-adjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy(EBRT)
A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer
ARMOR2:A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer2014
A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients with Castration-Resistant Prostate Cancer
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184)Versus Prednisone in Metastatic Castration-resistant Prostate Cancer Patients Who Have Received Prior Docetaxel and Prior Abiraterone or MDV3100
A Three arm randomized, open-label Phase II study of radium-223 dichloride 50kBq/Kg versus 80 kBq/Kg and versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Open label phase two trial of RADium Ra 223 dichloride with concurrent administration of Abiraterone Acetate plus Prednisone in Castration-Resistant(Hormone-Refractory) Prostate Cancer Subjects with Symptomatic Bone Metastasis
A Randomized, Open-label, Multicenter, Phase 2b Study to Evaluate Physical Function, Including Balance and Daily Activity, in Participants With Castration-resistant Prostate Cancer Treated With Darolutamide or Enzalutamide
A Phase Ib/II Study of Ipatasertib (GDC-0068) or Apitolisib (GDC-0980) With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
BiomarkerStudy to Determine Frequency of DNA-repair Defects in Men With MetastaticProstate Cancer
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
Retreatment with Radium 223: 2 year follow up form an international, open label, ph 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O, Heinrich D, Mariados N, Mendez V, Keizman D, Thellenberg K, Peer A, Procopio G, Frank S, Pulkkanen K, Rosenbaum E, Severi S, Trigo J, TrandafirL, Wagner V, Li R, Nordquist, L. Prostate. 2019 Oct; 79 (14): 1683-1691. Epub 2019 Aug 23.
Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer.
Gupta S, Nordquist L, Fleming M, Berry W, Zhang J, Ervin L, Eisner J, Baskin-Bey E, Shore N. Clin Cancer Res 2018 Nov 1;24 (21)5225-5232.
DNA vaccines: an active immunization strategy for prostate cancer.
Wolchok J, Gregor PD, Nordquist L, Slovin S, Scher H. Semin Oncol. 2003 Oct;30(5): 659-666.
Clinical Correlates of Benefit from Ra223 Therapy in Metastatic Castration Resistant Prostate Cancer.
Alva A, Nordquist L, Daignault S, George S, Ramos J, Albany C, Isharwal S, McDonald M, Campbell G, Danchaivijitr P, Yentz S, Anand A, Yu E. Prostate. 2017 Apr; 77(5): 479-488.
Real-World Outcomes of Sipuleucel-T Treatment in PROCEED , a Prospective Registry of Men with Metastatic Castration Resistant Prostate Cancer.
Higano C, Armstrong A, Sartor O, Vogelzang N, Kantoff P, McLeod D, Pieczonka C, Penson D, Shore N, Vacirca J, Concepcion R Tutrone R, Nordquist L, Quinn D, Kassabian V, Scholz M, Harmon M, Tyler R, Chang N, Tang H, Cooperberg M. Cancer 2019 Dec1; 125(23) 4172-4180.
Second Line Hormonal Therapy for Men with Chemotherapy-Naive, Castration Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
Virgo K, Basch E, Loblaw D, Oliver T, Rumble R, Carducci M, Nordquist L, Taplin M, Winquist E, Singer E. J Clin Oncology 2017 Jun 10;35(17) 1952-1964.
eRADicAte: A Prospective Evaluation Combining Radium 223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients with Castration Resistant Prostate Cancer.
Shore N, Tutrone R, Mariados N, Nordquist L, Mehlhaff B, Steere K, Harrelson S. Clin Genitourin Cancer. 2018 Apr; 16 (2): 149-154.
Re-treatment with radium 223: First experience from an international, open label, phase 1/2 study in patients with Castration Resistant Prostate Cancer and bone metastases.
Sartor O, Heinrich D, Mariados N, Mendez V, Keizman D, Thellenberg K, Peer A, Procopio G, Frank S, Pulkkanen K, Rosenbaum E, Severi S, Trigo P, Wagner V, Li R, Nordquist L. Ann Oncol 2017 Oct 1; 28(10): 2464-2471.
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase 1 and 2 Studies: Galeterone for the Treatment of Castration Resistant Prostate Cancer
Montgomery B, Eisenberger M, Rettig M, Chu F, Pili R, Stephenson J, Vogelzang N, Koletsky A, Nordquist L, Edenfield W, Mamlouk K, Ferrante K, Taplin M. Clin Cancer Res 2016 Mar15; 22 (6): 1356-63
Randomized Open Label Phase 3 Trial for Docetaxel Plus High Dose Calcitriol vs Docetaxel plus Prednisone for Patients with Metastatic Castration Resistant Prostate Cancer
Scher H, Jia X, Chi K deWit R, Berry W, Albers P, Henick B, Waterhouse D, Ruether D, Rosen P, Meluch A, Nordquist L, Venner P, Heidenreich A, Chu L, Heller G. J Clin Oncol. 2011 Jun 1; 29 (16): 2191-8.
Rapid Androgen Cycling as a Treatment for Patients with Prostate Cancer.
Feltquate D, Nordquist L, Eicher C, Morris M, Smaletz, Slovin S, Curley T, Wilton A, Fleisher M, Heller G, Scher H.
Clin Cancer Res 2006 Dec 15; 12(24): 7414-21.
Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients with Metastatic Castration Resistant Prostate Cancer: A Dept of Defense Prostate Cancer Clinical Trials Consortium Randomized Ph 2 Trial of Intermittent Docetaxel with Prednisone with or without GM-CSF.
Aggarwal R, Beer T, Weinberg V, Higano C, Taplin M, Ryan C, Lin A, Alumkal J, Graff J, Nordquist L, Herrera I, Small E. Clin Genitourin Cancer. 2015 Jun;13(3): 191-8.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
Smith M, Saad F, Chowdhury S, Ourdard S, Hadaschik B, Graff J, Olmos D, Mainwaring P, Lee J, Uemura H, Lopez-Gitlitz A, Trudel GEspina B, shu Y, Park Y, Rackoff W, Yu M, Small E, SPARTAN Investigators. N Endl J Med 2018 Apr 12;378(15): 1408-1418
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Fizazi K, Shore N, Tammela T, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja, Smith M, ARAMIS Investigators. N Engl J Med 2019 Mar 28; 380 (13): 1235-1246
Abiraterone and increased survival in metastatic prostate cancer
de Bono J, Logotheitis C, Molina A, Fizazi K, North S, Chu L, Chi K, Jones R, Goodman O, Saad F, Staffurth J, Mainwaring P, Harland S, Flaig T, Hutson T, Cheng T, Patterson H, Hainworth J, Ryan C, Sternberg C, Ellard S, Flechon A, Saleh M, Scholz M, Esftathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq C, Scher H; COU-AA-301 Investigators. N Engl J Med 2011 May 26; 364(21): 1995-2005.
Abiraterone in metastatic prostate cancer without previous chemotherapy
Ryan CJ, Smith M, de Bono J, Molina A, Logothetis C, de Souza P, Fizazi K, Mainwaring P, Piulats J, Ng S, Carles J, Mulders P, Basch E, Small E, Saad F, Schrijvers D, Van Poppel H, Mukherjee S, Suttmann H, Gerritsen W, Glaig T, George D, Yu E, Efstathiou e, Pantuck A, Winquist E, Higano C, Taplin M, Park Y, Kheoh T, Griffin T, Scher H, Rathkopf E; COU-AA-302 Investigators. Lancet Oncol 2015 Feb; 16(2): 152-60
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
Sternberg C, Fizazi K, Saad F, Shore N, De Giorgi U, Penson D, Ferreira U, Efstathiou E, Madziarska K, Kolinsky M, Cubero D, Noerby B, Zohren F, Lin X, Modelska K, Sugg J, Steinberg J, Hussain M; PROSPER Investigators. N Engl J Med 2020 Jun 4; 382(23): 2197-2206.